Cramer's lightning round: I prefer Intuit over Mogo
Cel-Sci Corporation : "Look, all I can tell you is that these companies just have nine lives, these immunotherapy companies. And in the end, one of the big drug companies tend to buy them because they need growth."

Endeavor Group Holdings : "I thought [acquiring] OpenBet is a good idea, and they got a good price. Now, Endeavor is my agent, so let's take it with a grain of salt. But ... the stock seems inexpensive and there is a return to entertainment, so I think that is good. I like betting, too, in general. A lot of people feel it's got too crowded."

Community Health Systems : "Everybody seems to always want to buy Community Health or Tennant when they should be buying HCA , which I think once again is going to blow away the numbers."

ZoomInfo Technologies : "You know, look, I think these are all companies that look, to me, a lot like Salesforce, OK? There's a bunch of them that look just like Salesforce, and a lot of them are good, and ZoomInfo is good. Me, I'm a Salesforce guy. It's what my charitable trust owns, and if you follow what we are doing in the CNBC Investment Club, you will know why I like Salesforce more than any of these companies."

Mogo Inc .: "Fintech, free credit score. You know what that says to me? Intuit. The one you should be in is [stock ticker] INTU. They don't miss quarters. They keep coming on, they do a fantastic job. That's the one I want you in."

BioNano Genomics : "Controversial. OK, I mean this is one of those stocks, the volume is such that it makes me feel like it's a meme stock. If I say something bad about it, the people who are in it are going to say, 'Jim, you don't know it.' I will tell you this: It's a big spec. It's all there is to it. It's a giant speculation biotech, and if you want to be in one of those, it could go down 50%, it could be up 50%."

Blade Air Mobility : "We praised it. We did a piece about it. I've used it, I think it's a terrific service. Yes, I paid for it, less anyone think I didn't. But this is what really matters, OK? This stock is so stuck because its cohort is stuck. If Blade were just an IPO, I'm telling you this thing would be at $15, $16, but it isn't and therefore it just is very hard to [get momentum] even as I think a lot of people feel it's got a very good business model."

Butterfly Network : "This is another one. ... It's not working, what can I say? It's just not working."